Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

Front Immunol. 2018 Mar 2:9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

¹ Department of Medical Oncology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
² Unit of Clinical Epidemiology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
³ Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
⁴ Department of Health Sciences, University of Genova, Genova, Italy.
⁵ Unit of Cellular Biology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
⁶ Intergruppo Melanoma Italiano (IMI) and Department of Internal Medicine, University of Genova, Genova, Italy.
⁷ Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy.
⁸ Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione 'G. Pascale', Naples, Italy.
⁹ Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy.
¹⁰ Medical Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
¹¹ Department of Medical Oncology, Molecular Genetics Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II,"Bari, Italy.
¹² Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
¹³ Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
¹⁴ Immunotherapy and Cell Therapy, IRCCS-IRST, Meldola, Italy.

Abstract

[This corrects the article on p. 386 in vol. 8, PMID: 28446908.].

Keywords: CTLA-4 variants; best overall response; ipilimumab; melanoma; overall survival; predictive/prognostic factor.